You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東曜藥業-B(1875.HK)2024年淨利3475.7萬元 首次實現扭虧爲盈
格隆匯 03-12 07:12
東曜藥業-B(1875.HK)公告,截至2024年12月31日止年度全年業績,公司業績超預期,全年營收人民幣1,098,329千元,同比增長41%。2024年首次實現扭虧爲盈,全年淨利潤達人民幣34,757千元。造血能力持續增強,經營活動現金淨額連續三年持續正向,2024年達人民幣116,403千元。CDMO業務呈現強勁發展潛力,漏鬥效應明顯;得益於前沿的技術平臺,強化前端引流,早期項目大幅增加。全年新增項目58個,其中ADC48個,累計至153個項目。全年成功獲得2個pre-BLA(上市前關鍵臨牀及新藥申報階段項目)項目,累計在手8個,充分展示了公司CDMO後期商業化項目卓越能力,強化公司未來收入預期潛力。在手已簽約未完成訂單達人民幣1.91億元,同比增長39%。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account